News

BiTE antibodies: Bayer does it again
Enlarge image

BusinessGermany

BiTE antibodies: Bayer does it again

25.04.2012 - Even after the takeover of German-American Micromet Inc. by Amgen, Bite antibody technology remains interesting for other pharma partners.

Berlin/Martinsried  –  Bayer HealthCare has agreed to extend its collaboration with Amgen Research GmbH, as the former Micromet site in Munich is called today. Bayer and its partner will develop another new Bispecific T cell Engager antibody against an undisclosed target expressed in multiple tumours. The German pharma had forged a first option, collaboration and license agreement with Micromet in January 2009 to discover and develop a novel BiTE antibody targeting PSMA (prostate specific membrane antigen) for the treatment of patients with prostate cancer.  Amgen acquired Micromet in March this year for US-$1.2bn and promised to keep the German site as its largest research centre outside the US. Under the terms of the present agreement, Bayer will collaborate with Amgen Research from the research phase through to the completion of Phase I clinical trials, upon which Bayer will assume full control of further development and commercialisation of the product candidate. The cooperation also includes evaluation of BiTE antibodies with an extended serum half-life. Financial details of the collaboration were not disclosed. Meanwhile, the development of the initial BiTE antibody resulting from the 2009 collaboration progresses according to plan and the initiation of the clinical Phase I trial could start as early as in the second half of 2012.

http://www.european-biotechnology-news.com/news/news/2012-02/bite-antibodies-bayer-does-it-again.html

AntibodiesDenmarkNetherlands

22.05.2015 Dutch arGEN-X and Danish LEO Pharma are pairing up to develop antibody-based treatments for the chronic inflammation that causes many skin conditions.

M&ANetherlandsGermanyEU

12.05.2015 US pharma is coming to European biotech to fill their pipeline. Pfizer is paying €77.5m for an option on Dutch AM-Pharma, while Juno Therapeutics acquired German biotech Stage Cell Therapeutics for around €72m.

Rare diseasesItalyGermanyPoland

15.05.2015 Rome-based pharmaceutical group Sigma-Tau has sold its blood cancer drug programme Oncaspar to US company Baxter, who aims to spin out its biopharma business.



BiologicsFinlandNetherlandsEU

26.05.2015 The Finnish Medicines Agency Fimea has joined the Dutch MEB in its stance on the interchangeability of biosimilars. The Fimea now sees physician-driven switching of biologics as unproblematic.

SurveyGermany

06.05.2015 More revenue, more staff, more funding: in the German biotech industry, all signs are pointing towards growth.

M&AUKSweden

18.05.2015 Double deal for allergy: UK’s speciality biopharma Circassia is boosting its asthma pipeline with the acquisition of Swedish asthma specialist Aerocrine as well as fellow British Prosonix.

FinancingUK

20.05.2015 The Scottish Government has announced it will double the amount of funds for rare diseases. The New Medicines Fund that was created last year for this purpose will be increased to £80m (€112m).

M&ASwitzerland

04.05.2015 Swiss crop chemical maker Syngenta AG is in talks with US company Monsanto to discuss a possible merger, insiders say.

BiofuelsEU

30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.

Events

All Events

Partner-Events

Frankfurt am Main (DE)

ACHEMA 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MAGFORCE6.55 EUR9.17%
  • WILEX4.29 EUR5.41%
  • VITA 345.75 EUR1.77%

FLOP

  • EPIGENOMICS5.51 EUR-3.67%
  • BASILEA126.80 CHF-3.43%
  • BAYER129.15 EUR-3.19%

TOP

  • SYNGENTA425.50 CHF35.3%
  • EVOLVA1.79 CHF13.3%
  • BASILEA126.80 CHF13.1%

FLOP

  • CYTOS0.64 CHF-36.6%
  • MEDIGENE8.30 EUR-24.3%
  • THERAMETRICS0.07 CHF-12.5%

TOP

  • WILEX4.29 EUR436.2%
  • SANTHERA90.35 CHF330.2%
  • FORMYCON29.00 EUR322.7%

FLOP

  • MOLOGEN4.93 EUR-53.7%
  • BIOFRONTERA2.25 EUR-26.9%
  • PAION2.54 EUR-26.8%

No liability assumed, Date: 29.05.2015